Serum follicle-stimulating hormone level is associated with human epidermal growth factor receptor type 2 and Ki67 expression in post-menopausal females with breast cancer

Oncology Letters

Volumn 6, Issue 4, 2013, Pages 1128-1132

  Zhou, Jun ^a,b   Chen, Yiding ^b   Huang, Yiting ^a   Long, Jinpei ^b   Wan, Fang ^b   Zhang, Suzhan ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Zhejiang University School of Medicine   (China)

Author keywords

Breast cancer; Follicle stimulating hormone; Human epidermal growth factor receptor 2; Ki67; Post menopausal

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLLITROPIN; GONADOTROPIN; KI 67 ANTIGEN; MOLECULAR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER STAGING; CELL PROLIFERATION; DISEASE ASSOCIATION; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; LUTEINIZING HORMONE BLOOD LEVEL; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POSTMENOPAUSE; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY;

EID: 84881580888     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1516     Document Type: Article

References (34)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CACancer J Clin 62: 10-29, 2012.
2. Yang W and Guan L: Bridging the US and China together to conquer cancer: report of the 4th annual meeting of the US Chinese Anti-Cancer Association (USCACA). Chin J Cancer 31: 315-318, 2012.
3. Yang L, Parkin DM, Ferlay J, Li L and Chen Y: Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 14: 243-250, 2005.
4. Zheng S, Bai JQ, Li J, et al: The pathologic characteristics of breast cancer in China and its shift during 1999-2008: A national-wide multicenter cross-sectional image over 10 years. Int J Cancer 131: 2622-2631, 2012.
5. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science244: 707-712, 1989.
6. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM and Hortobagyi GN: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14: 320-368, 2009.
7. Lopez F, Belloc F, Lacombe F, et al: Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry12: 42-49, 1991.
8. Goldhirsch A, Wood WC, Coates AS, et al: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747, 2011.
9. Eliassen AH, Tworoger SS and Hankinson SE: Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women. Int J Cancer 120: 1536-1541, 2007.
10. Tworoger SS and Hankinson SE: Prolactin and breast cancer risk. Cancer Lett 243: 160-169, 2006.
11. Kuijper TM, Ruigrok-Ritstier K, Verhoef-Post M, et al: LH receptor gene expression is essentially absent in breast tumor tissue: implications for treatment. Mol Cell Endocrinol 302: 58-64, 2009.
12. Bodek G, Rahman NA, Zaleska M, et al: A novel approach of targeted ablation of mammary carcinoma cells through luteinizing hormone receptors using Hecate-CGbeta conjugate. Breast Cancer Res Treat 79: 1-10, 2003.
13. Meduri G, Charnaux N, Loosfelt H, et al: Luteinizing hormone/human chorionic gonadotropin receptors in breast cancer. Cancer Res57: 857-864, 1997.
14. Meduri G, Charnaux N, Spyratos F, Hacene K, Loosfelt H and Milgrom E: Luteinizing hormone receptor status and clinical, pathologic, and prognostic features in patients with breast carcinomas. Cancer 97: 1810-1816, 2003.
15. Caffier H and Brandau H: Serum tumor markers in metastatic breast cancer and course of disease. Cancer Detect Prev6: 451-457, 1983.
16. Tsalacopoulos G and Bloch B: Ectopic production of the beta subunit of human chorionic gonadotrophin by malignant ovarian neoplasms. S Afr Med J 62: 487-488, 1982.
17. Ben-Josef E, Yang SY, Ji TH, et al: Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol 161: 970-976, 1999.
18. Davies S, Bax CM, Chatzaki E, Chard T and Iles RK: Regulation of endometrial cancer cell growth by luteinizing hormone (LH) and follicle stimulating hormone (FSH). Br J Cancer 83: 1730-1734, 2000.
19. Chen FC, Oskay-Ozcelik G, Bühling KJ, et al: Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer. Anticancer Res 29: 1575-1578, 2009.
20. Wayne CM, Fan HY, Cheng X and Richards JS: Follicle-stimulating hormone induces multiple signaling cascades: evidence that activation of Rous sarcoma oncogene, RAS, and the epidermal growth factor receptor are critical for granulosa cell differentiation. Mol Endocrinol 21: 1940-1957, 2007.
21. Hunzicker-Dunn M and Maizels ET: FSH signaling pathways in immature granulosa cells that regulate target gene expression: branching out from protein kinase A. Cell Signal 18: 1351-1359, 2006.
22. Choi JH, Choi KC, Auersperg N and Leung PC: Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 89: 5508-5516, 2004.
23. Huhtaniemi I: Are gonadotrophins tumorigenic-a critical review of clinical and experimental data. Mol Cell Endocrinol329: 56-61, 2010.
24. Pujol P, Daures JP, Brouillet JP, et al: A prospective prognostic study of the hormonal milieu at the time of surgery in premenopausal breast carcinoma. Cancer 91: 1854-1861, 2001.
25. Zreik TG, Mazloom A, Chen Y, et al: Fertility drugs and the risk of breast cancer: a meta-analysis and review. Breast Cancer Res Treat 124: 13-26, 2010.
26. Sprengel R, Braun T, Nikolics K, Segaloff DL and SeeburgPH: The testicular receptor for follicle stimulating hormone: structure and functional expression of cloned cDNA. Mol Endocrinol4: 525-530, 1990.
27. Kelton CA, Cheng SV, Nugent NP, et al: The cloning of the human follicle stimulating hormone receptor and its expression in COS-7, CHO, and Y-1 cells. Mol Cell Endocrinol 89: 141-151, 1992.
28. Van Loy T, Vandersmissen HP, Van Hiel MB, et al: Comparative genomics of leucine-rich repeats containing G protein-coupled receptors and their ligands. Gen Comp Endocrinol 155: 14-21, 2008.
29. Hsu SY, Kudo M, Chen T, et al: The three subfamilies of leucine-rich repeat-containing G protein-coupled receptors (LGR): identification of LGR6 and LGR7 and the signaling mechanism for LGR7. Mol Endocrinol 14: 1257-1271, 2000.
30. Garde SV, Sheth AR, Joseph R, Panchal CJ, Chinoy RF and ShethNA: Occurrence and de novo biosynthesis of follicle stimulating hormone (FSH) in benign and malignant conditions of human breast. Cancer Lett 75: 1-9, 1993.
31. Wang N, Wang B, Wang Y and Hu J: Estrogen receptor positive operable breast cancer: does menopausal status impact on HER2 and progesterone receptor status? Breast 20: 519-524, 2011.
32. Hernández L, Nuñez-Villarl MJ, Martínez-Arribas F, Pollán M and Schneider J: Circulating hormone levels in breast cancer patients. Correlation with serum tumor markers and the clinical and biological features of the tumors. Anticancer Res 25: 451-454, 2005.
33. Choi JH, Chen CL, Poon SL, Wang HS and Leung PC: Gonadotropin-stimulated epidermal growth factor receptor expression in human ovarian surface epithelial cells: involvement of cyclic AMP-dependent exchange protein activated by cAMP pathway. Endocr Relat Cancer 16: 179-188, 2009.
34. Zhang Z, Jia L, Feng Y and Zheng W: Overexpression of follicle-stimulating hormone receptor facilitates the development of ovarian epithelial cancer. Cancer Lett 278: 56-64, 2009.